Dextenza in the Post-op Management of Vitreoretinal Surgeries

Inclusion Criteria: * Men and women \>18 years old * Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction. Exclusion Criteria: * Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and/or implant of a drug delivery system * History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye * Structural lid abnormalities such as ectropion or entropion in surgical eye * Ongoing use of systemic narcotic pain relievers * Presence of any intraocular inflammation (cells and flare) in the study eye at screening/baseline * Pain score greater than "0" on the ocular pain assessment in the study eye at screening/baseline * Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes * Other ocular surgeries or procedures during the study period and/or 6 months prior * Intraoperative complications * Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled. * Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication. * Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery. * Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively. * Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure * Are pregnant or nursing/lactating * Participation as a subject in any clinical study within the 30 days prior to randomization. * Surgeries using 20 gauge or 23 gauge instruments.